ABBV
AbbVie Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$291.39
+1.88%Aug 28, 2026, 00:18 UTC
China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.
Source:Aug 27, 2026, 06:00 UTC
AbbVie submitted a regulatory application to the European Medicines Agency seeking approval for SKYRIZI (risankizumab) subcutaneous induction for adults with moderately to severely active Crohn's disease, supported by data from the Phase 3 AFFIRM study.
Source:Aug 25, 2026, 15:45 UTC
Richard Gonzalez, former CEO of AbbVie, listed his Trump Tower condo for sale at $3.9 million.
Source:Aug 25, 2026, 08:09 UTC
Donaldson Capital Management LLC increased its stake in AbbVie Inc. by 0.7% during the quarter, acquiring 3,553 additional shares, bringing its total holdings to 485,608 shares valued at $122.20 million.
Source:Aug 25, 2026, 08:09 UTC
Convergence Financial LLC increased its stake in AbbVie Inc. by 91.7% during the quarter, acquiring an additional 2,713 shares to hold 5,670 shares, as disclosed in an SEC filing.
Source:Aug 24, 2026, 00:00 UTC
Oruka Therapeutics, Inc. appointed Todd Edwards as Chief Commercial Officer, effective with a base salary of $525,000, a target bonus of 40% of annual base salary, a signing bonus of $200,000, and equity grants including a stock option for 20,000 shares and restricted stock units for 100,000 shares of Oruka common stock.
Aug 23, 2026, 08:41 UTC
Gateway Wealth Partners LLC reduced its stake in AbbVie Inc. by 40.8% during the second quarter, selling 11,835 shares and retaining 17,158 shares, as disclosed in a recent SEC filing.
Source:Aug 22, 2026, 09:45 UTC
AbbVie EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on August 14th.
Source:Aug 21, 2026, 11:48 UTC
AbbVie presented clinical data from its lung cancer research programs at the 2026 World Conference on Lung Cancer, including Phase 1b results for ABBV-1480 and a Phase 1b/2 study for telisotuzumab adizutecan.
Source:Aug 21, 2026, 11:30 UTC
AbbVie announced a modified Dutch auction tender offer to repurchase up to $230 million of its common stock.
Source:Aug 19, 2026, 19:38 UTC
Biopharma stocks including AbbVie, Amgen, Eli Lilly, Johnson & Johnson, and Merck rallied on Wednesday, with Merck jumping 12.4%.
Source:Aug 16, 2026, 13:57 UTC
Zelgen Biopharmaceuticals reached a BD collaboration with AbbVie on ZG006, recognizing 662 million yuan in technology licensing revenue, with both parties accelerating global development.
Aug 6, 2026, 19:00 UTC
The Trump administration quietly changed a policy that delayed Medicare price negotiations for an AbbVie drug by seven years, according to an advocacy group's analysis.
Source:Aug 6, 2026, 00:00 UTC
REGENXBIO Inc. received a $100 million milestone payment from AbbVie for the first patient dosing in the NAAVIGATE trial.
Source:Aug 5, 2026, 09:57 UTC
Rongchang Biologics signed an exclusive licensing agreement with AbbVie, granting AbbVie exclusive rights to develop, produce, and commercialize RC148 outside Greater China.
Aug 4, 2026, 12:00 UTC
Allergan Aesthetics, an AbbVie company, announced that the U.S. FDA has accepted for review its supplemental Biologics License Application for BOTOX Cosmetic for the temporary improvement of masseter muscle prominence in adults.
Source:Aug 3, 2026, 14:05 UTC
AbbVie Inc. stock reached a 52-week high of $267.47 on June 29, 2026.
Source:Jul 29, 2026, 07:00 UTC
The European Commission approved AbbVie's RINVOQ (upadacitinib) for treating adults and adolescents with non-segmental vitiligo.
Source:Jul 27, 2026, 13:19 UTC
Sarepta Therapeutics appointed Michael Severino as its new CEO, effective July 28, succeeding Doug Ingram who is retiring.
Source:Jul 17, 2026, 12:00 UTC
The European Commission approved Allergan Aesthetics' Boey (trenibotulinumtoxinE) for use in Europe for temporary improvement of glabellar lines in adult patients.
Source:Jul 14, 2026, 12:05 UTC
SkinMedica launched a Regenerative Science Advisory Board and expanded its R&D facility and retail experiences.
Source:Jul 10, 2026, 16:15 UTC
The U.S. House Select Committee on the Chinese Communist Party launched a bipartisan investigation into five major American pharmaceutical companies over clinical trials conducted in China, including at hospitals linked to the People's Liberation Army and in Xinjiang province, sending letters demanding records by July 17.
Jul 3, 2026, 03:46 UTC
The U.S. House Select Committee on China sent an investigation letter to AbbVie, requesting explanations by July 17 regarding safety, IP protection, and ethical oversight of its clinical trials in China, including 17 in Xinjiang and 16 at military-affiliated institutions.
Source:Jun 23, 2026, 12:00 UTC
Allergan Aesthetics received Health Canada approval for Boey (trenibotulinumtoxinE) for temporary improvement of glabellar lines in adults.
Source: